| abstract |
The disclosure relates to 4-aminocarbonyl-pyrimidine derivatives of formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals, wherein the variables shown in formula (I) are as defined in the specification. |